Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 3/20 | 0.50 |
| ▸ | CMA1 | P23946 | 2/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.49 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.42 |
| ▸ | TDP2 | O95551 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062478 | 0.89 | PDE3B (0.59) | SLC6A11AHRPDK2PDE3BPDE3A | |
| SCHEMBL16090367 | 0.80 | PDE3B (0.52) | SLC6A11AHRPDK2PDE3BPDE3A | |
| SCHEMBL16090265 | 0.79 | CRBN (0.52) | AHRCMA1CRBNEIF2AK2PDK2 | |
| SCHEMBL4408889 | 0.78 | TDP2 (0.65) | AHRCMA1CRBNEIF2AK2PDK2 | |
| SCHEMBL6746640 | 0.77 | AHR (0.49) | AHRCMA1CRBNEIF2AK2PDK2 | |
| SCHEMBL6743691 | 0.76 | AHR (0.55) | AHRCMA1CRBNEIF2AK2PDK2 | |
| SCHEMBL6742551 | 0.76 | CRBN (0.50) | AHRCMA1CRBNEIF2AK2PDK2 | |
| SCHEMBL6743185 | 0.76 | CRBN (0.50) | AHRCMA1CRBNEIF2AK2PDK2 | |
| SCHEMBL29850050 | 0.76 | PDE3B (0.76) | AHRCMA1CRBNEIF2AK2PDK2 | |
| SCHEMBL6744175 | 0.76 | PDE3B (0.76) | AHRCMA1CRBNEIF2AK2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129253-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-31 | — | — | US | disclosed |
| US-7105529-B2 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-12 | — | — | US | disclosed |
| US-6818632-B2 | 3-(anilinomethylene)oxindoles | SMITHKLINE BEECHAM CORPORATION | 2004-11-16 | — | — | US | disclosed |
| US-20040191210-A1 | Compounds | GLENNON KIMBERLEY CAROLINE (US) | 2004-09-30 | — | — | US | disclosed |
| US-6689806-B1 | MODULATING PROTEIN KINASES AND RELATED SIGNAL TRANSDUCTION PATHWAYS | SUGEN, INC. | 2004-02-10 | — | — | US | disclosed |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SMITHKLINE BEECHAM CORPORATION | 2003-04-10 | — | — | US | disclosed |
| US-6498176-B1 | INHIBITING TUMOR GROWTH VIA INHIBITION OF TUMOR-RELATED ANGIOGENESIS | SMITHKLINEBEECHAM CORPORATION | 2002-12-24 | — | — | US | disclosed |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | GLENNON KIMBERLEY CAROLINE (US) | 2002-07-25 | — | — | US | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1165513-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | Sugen, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000056709-A1 | INDOLINONE COMPOUNDS AS KINASE INHIBITORS | SUGEN, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040191210-A1 | Compounds | CDK1, AKT1, RPS6KA1 | SLC6A11 4748/4885AHR 3651/4885CMA1 2760/4885 |
| US-20020099071-A1 | Protein tyrosine kinase and protein serin/threonine kinase inhibitory activity; anticancer agents; treating chemotherapy induced alopecia | PRKDC, PRKX, BMX | SLC6A11 4801/4885AHR 2606/4885CMA1 3386/4885 |
| US-20030069430-A1 | Substituted oxindole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors and compositions and methods of treating chemotherapy and radiation therapy side effects | SRC, CDK2, CDK1 | SLC6A11 4858/4885AHR 279/4885CMA1 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.